References
- Sandison J. A new method for the microscopic study of living growing tissues by the introduction of a transparent chamber in the rabbits ear. Anat Rec 1924;28:281–7.
- Algire G. An adaption of the transparent chamber technique to the mouse. J Natl Cancer Inst 1943;4:1–11.
- Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–57.
- Makale M. Intravital imaging and cell invasion. Methods Enzymol 2007;426:375–401.
- Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275–88.
- Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24–40.
- Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299–309.
- Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008;35:274–85.
- Lehr HA, Leunig M, Menger MD, Nolte D, Messmer K. Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am J Pathol 1993;143:1055–62.
- Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol 2006;45:300–5.
- Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 1998;8:377–85.
- Margaritescu C, Pirici D, Simionescu C, Mogoanta L, Raica M, Stinga A, VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom J Morphol Embryol 2009;50:527–48.
- Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29:1140–5.
- Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10:247–57.
- Bozec A, Sudaka A, Fischel J, Brunstein M, Grimaldi M, Milano G. Reply: Did animal offer relevant model for bevacizumab testing? Br J Cancer 2008;99:1556.
- Sumen C, Mempel TR, Mazo IB, von Andrian UH. Intravital microscopy: visualizing immunity in context. Immunity 2004;21:315–29.
- Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung cancer xenografts. Clin Cancer Res 2000;6:2075–86.
- Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts. Oral Oncol 2011;47:459–66.
- Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010;16:1973–8.
- Wang Y, Dong L, Bi Q, Li X, Wu D, Ge X, Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice. Target Oncol 2010;5:237–43.